FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988624114> ?p ?o ?g. }

• W1988624114 endingPage "e5" @default.
• W1988624114 startingPage "e1" @default.
• W1988624114 abstract "Cholecystokinin (CCK)-receptor antagonists have been found to markedly reduce the severity of pancreatitis and improve survival in experimental animal models of acute pancreatitis. CCK appears to play an important role in the development and progression of acute pancreatitis, and the recent development of CCK antagonists has provided a new approach to the treatment of acute pancreatitis in humans.The therapeutic efficacy of a CCK-A receptor antagonist, loxiglumide, in patients with painful acute attacks of chronic pancreatitis was evaluated.A multicenter dose-response controlled trial was conducted at 110 institutions in Japan from June 1993 to December 1994. Chronic pancreatitis was diagnosed for all patients on the basis of the Japanese criteria for chronic pancreatitis. Two-hundred seven patients were randomized to oral treatment with loxiglumide (300, 600, and 1,200 mg/d) or placebo for 4 weeks. The efficacy of treatment was evaluated on the basis of clinical symptoms, physical signs, and serum pancreatic enzyme levels. The groups were comparable with respect to age, sex, etiology, complications, and previous treatment.The improvement rate of the abdominal and/or back pain was 46% in the loxiglumide 300-mg group, 59% in the 600-mg group, and 52% in the 1,200-mg group, and it was 36% in the placebo group (600 mg versus placebo: p < 0.05). The physical signs evaluated--abdominal tenderness and resistance--improved in all three loxiglumide groups, and the serum pancreatic amylase and trypsin levels decreased significantly in the 600-mg group (p < 0.05). The overall clinical improvement rate was 46% in the 300-mg loxiglumide group, 58% in the 600-mg group, and 52% in the 1,200-mg group, and it was 34% in the placebo group.These results indicate that oral administration of loxiglumide may be useful in the treatment of patients with acute, painful attacks of chronic pancreatitis, and 600 mg/d is recommended as a beneficial dosage." @default.
• W1988624114 created "2016-06-24" @default.
• W1988624114 creator A5047452461 @default.
• W1988624114 creator A5075202285 @default.
• W1988624114 creator A5084338218 @default.
• W1988624114 creator A5089856009 @default.
• W1988624114 date "2002-07-01" @default.
• W1988624114 modified "2023-10-16" @default.
• W1988624114 title "Clinical Evaluation of Oral Administration of a Cholecystokinin-A Receptor Antagonist (Loxiglumide) to Patients with Acute, Painful Attacks of Chronic Pancreatitis: A Multicenter Dose–Response Study in Japan" @default.
• W1988624114 cites W1497506244 @default.
• W1988624114 cites W1527869883 @default.
• W1988624114 cites W1554441898 @default.
• W1988624114 cites W1812182962 @default.
• W1988624114 cites W1968597788 @default.
• W1988624114 cites W1972714301 @default.
• W1988624114 cites W1986546610 @default.
• W1988624114 cites W2004061807 @default.
• W1988624114 cites W2005390739 @default.
• W1988624114 cites W2010825319 @default.
• W1988624114 cites W2012879411 @default.
• W1988624114 cites W2016961829 @default.
• W1988624114 cites W2021258090 @default.
• W1988624114 cites W2028646460 @default.
• W1988624114 cites W2030854777 @default.
• W1988624114 cites W2031916956 @default.
• W1988624114 cites W2048131650 @default.
• W1988624114 cites W2060386265 @default.
• W1988624114 cites W2062081592 @default.
• W1988624114 cites W2064295011 @default.
• W1988624114 cites W2065609611 @default.
• W1988624114 cites W2066282763 @default.
• W1988624114 cites W2068155141 @default.
• W1988624114 cites W2076956367 @default.
• W1988624114 cites W2080291985 @default.
• W1988624114 cites W2083347538 @default.
• W1988624114 cites W2140762297 @default.
• W1988624114 cites W2235590001 @default.
• W1988624114 cites W4233778030 @default.
• W1988624114 doi "https://doi.org/10.1097/00006676-200207000-00003" @default.
• W1988624114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12131781" @default.
• W1988624114 hasPublicationYear "2002" @default.
• W1988624114 type Work @default.
• W1988624114 sameAs 1988624114 @default.
• W1988624114 citedByCount "43" @default.
• W1988624114 countsByYear W19886241142012 @default.
• W1988624114 countsByYear W19886241142013 @default.
• W1988624114 countsByYear W19886241142014 @default.
• W1988624114 countsByYear W19886241142015 @default.
• W1988624114 countsByYear W19886241142017 @default.
• W1988624114 countsByYear W19886241142018 @default.
• W1988624114 countsByYear W19886241142019 @default.
• W1988624114 countsByYear W19886241142021 @default.
• W1988624114 countsByYear W19886241142022 @default.
• W1988624114 crossrefType "journal-article" @default.
• W1988624114 hasAuthorship W1988624114A5047452461 @default.
• W1988624114 hasAuthorship W1988624114A5075202285 @default.
• W1988624114 hasAuthorship W1988624114A5084338218 @default.
• W1988624114 hasAuthorship W1988624114A5089856009 @default.
• W1988624114 hasConcept C126322002 @default.
• W1988624114 hasConcept C134018914 @default.
• W1988624114 hasConcept C142724271 @default.
• W1988624114 hasConcept C170493617 @default.
• W1988624114 hasConcept C204787440 @default.
• W1988624114 hasConcept C27081682 @default.
• W1988624114 hasConcept C2775967933 @default.
• W1988624114 hasConcept C2776079162 @default.
• W1988624114 hasConcept C2776670229 @default.
• W1988624114 hasConcept C2776737053 @default.
• W1988624114 hasConcept C2776885963 @default.
• W1988624114 hasConcept C2777593968 @default.
• W1988624114 hasConcept C2778764654 @default.
• W1988624114 hasConcept C2780955771 @default.
• W1988624114 hasConcept C32110497 @default.
• W1988624114 hasConcept C71924100 @default.
• W1988624114 hasConcept C90924648 @default.
• W1988624114 hasConceptScore W1988624114C126322002 @default.
• W1988624114 hasConceptScore W1988624114C134018914 @default.
• W1988624114 hasConceptScore W1988624114C142724271 @default.
• W1988624114 hasConceptScore W1988624114C170493617 @default.
• W1988624114 hasConceptScore W1988624114C204787440 @default.
• W1988624114 hasConceptScore W1988624114C27081682 @default.
• W1988624114 hasConceptScore W1988624114C2775967933 @default.
• W1988624114 hasConceptScore W1988624114C2776079162 @default.
• W1988624114 hasConceptScore W1988624114C2776670229 @default.
• W1988624114 hasConceptScore W1988624114C2776737053 @default.
• W1988624114 hasConceptScore W1988624114C2776885963 @default.
• W1988624114 hasConceptScore W1988624114C2777593968 @default.
• W1988624114 hasConceptScore W1988624114C2778764654 @default.
• W1988624114 hasConceptScore W1988624114C2780955771 @default.
• W1988624114 hasConceptScore W1988624114C32110497 @default.
• W1988624114 hasConceptScore W1988624114C71924100 @default.
• W1988624114 hasConceptScore W1988624114C90924648 @default.
• W1988624114 hasIssue "1" @default.
• W1988624114 hasLocation W19886241141 @default.
• W1988624114 hasLocation W19886241142 @default.
• W1988624114 hasOpenAccess W1988624114 @default.
• W1988624114 hasPrimaryLocation W19886241141 @default.
• W1988624114 hasRelatedWork W1982594208 @default.

• next